Aligos Therapeutics, Inc. Common Stock vs. Moderna, Inc. Common Stock
ALGS
Aligos Therapeutics, Inc. Common Stock
$5.68 +3.46%
VS MRNAModerna, Inc. Common Stock
$194.82 +6.98%
Moderna, Inc. Common Stock (MRNA) comes out ahead, leading on 5 of 8 compared factors.
Size & Scale
| ALGS | MRNA | |
|---|---|---|
| Market Cap | $34.28 million | $72.70 billion |
| Revenue (TTM) | $31.52 million | $2.23 billion |
| Net Income (TTM) | $-75,962,000 | $-3,151,000,000 |
MRNA leads on 2 of 3 size & scale factors.
Valuation
| ALGS | MRNA | |
|---|---|---|
| Price / Book | 1.08 | 10.75 |
| Price / Sales | 1.09 | 32.63 |
ALGS leads on 2 of 2 valuation factors.
Profitability
| ALGS | MRNA | |
|---|---|---|
| Net Margin | -241.01% | -141.43% |
| Return on Equity | -238.24% | -46.61% |
MRNA leads on 2 of 2 profitability factors.
Risk & Sentiment
| ALGS | MRNA | |
|---|---|---|
| Short Interest | 31.30% | 0.01% |
MRNA leads on 1 of 1 risk & sentiment factors.
Dig deeper: ALGS overview, ALGS financials, MRNA overview, MRNA financials.
Comparisons use delayed, cached fundamental data and cover only the factors shown. For informational purposes only — not investment advice.